Latest Product Development News

Amotiv Limited reported a solid FY26 half-year result with revenue growth and margin pressures partly offset by its Amotiv Unified transformation program. The company maintained its FY26 guidance, highlighting strong cash flow and shareholder returns.

Amotiv Limited posted a resilient half-year result for December 2025, balancing modest revenue growth and margin pressures with strong cash flow and shareholder returns.

Amotiv Limited reported a 3.3% revenue increase to $520.5 million for the half year ended December 2025, alongside a 39.4% jump in net profit, driven by new business wins and operational efficiencies despite margin pressures in key segments.

Eden Innovations has appointed Dr Allan Godsk Larsen as Managing Director to spearhead its global growth, leveraging his deep expertise in carbon nanotube technology amid strong commercial momentum and significant debt reduction.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

CAR Group Limited reported a strong half-year result for the period ending 31 December 2025, with revenue up 8% and adjusted net profit rising 11.5%, driven by robust performance across Australia, North America, Latin America, and Asia.

Osteopore Limited has successfully raised the entire $5 million from the first tranche of its $20 million convertible notes issuance, securing funds to support ongoing operations and future growth.

RPMGlobal Holdings Limited shares will be suspended from the ASX following Federal Court approval of its acquisition by a Caterpillar subsidiary, marking a significant ownership change.

Cyclopharm Limited is accelerating its US market push for Technegas with a A$16 million capital raise following a record 2025 sales performance. The company aims to expand its US installations and advance new clinical applications beyond pulmonary embolism.

GCM Corporation is advancing its commercialisation strategy with multiple prototypes across key global markets and sectors, aiming for revenue in the first half of 2026.

Vitrafy Life Sciences has delivered key milestones in the first half of FY26, including a strategic partnership with IMV Technologies and progress in clinical studies, while maintaining a strong cash position to support its U.S. expansion and product launches.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.